Compare Corning Incorporated (GLW) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corning Incorporated vs State Street SPDR S&P Biotech ETF — how do they compare? Corning Incorporated trades at $167.38 (market cap $137.12B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Corning Incorporated pays a 0.7% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Corning Incorporated nearer its low. Which is the better fit depends on your goals.
| GLW | XBI | |
|---|---|---|
Market Cap | $137.12B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $255.79 | $164.28 |
52-Week Low | $64.52 | $86.92 |
Enterprise Value | $144.00B | — |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corning (GLW) trades at $167.02, up 5.88% over 24 hours, with a bearish technical signal but strong fundamental momentum. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS up 30% year-over-year. Revenue growth is accelerating, driven by optical communications and AI data center demand, though valuation multiples remain elevated. Recent news highlights analyst upgrades citing improved fundamentals post-sell-off.
Outlook is positive with a consensus price target of $193.33 (15.8% upside), supported by AI infrastructure growth and profitability improvements. Risks include high valuation sensitivity, competitive pressures, and execution challenges in scaling solar and automotive segments. Institutional sentiment is bullish with 56.75% buy ratings, but technical indicators warn of near-term overbought conditions.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
